Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials | Zendy

Ken Kauffman | Zendy; Dennis E. Doherty | Zendy; Kerwin | Zendy; Matiz-Bueno | Zendy; Knorr | Zendy; Shekar | Zendy; Gates | Zendy; Staudinger | Zendy

Open Access

Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials

Author(s) -

Ken Kauffman,

Dennis E. Doherty,

Kerwin,

Matiz-Bueno,

Knorr,

Shekar,

Gates,

Staudinger

Publication year - 2012

Publication title -

international journal of copd

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.394

H-Index - 67

eISSN - 1178-2005

pISSN - 1176-9106

DOI - 10.2147/copd.s29444

Subject(s) - medicine , placebo , copd , mometasone furoate , formoterol , morning , exacerbation , inhaler , clinical endpoint , area under the curve , randomized controlled trial , anesthesia , asthma , corticosteroid , budesonide , alternative medicine , pathology

The clinical efficacy and safety of a mometasone furoate/formoterol fumarate (MF/F) fixed-dose combination formulation administered via a metered-dose inhaler was investigated in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research